Media Library
Access photos, images, or videos for stories in development. If you are a member of the working press and need a resource that is not available on this website, please email your request to media@bms.com and we will make every effort to respond as soon as possible. Please read our terms for usage.
Key Facts
updated June 2023
ELIQUIS® (apixaban), $11.8 billion
REVLIMID® (lenalidomide), $10.0 billion
OPDIVO®(nivolumab), $8.2 billion
POMALYST® / Imnovid® (pomalidomide), $3.5 billion
ORENCIA® (abatacept), $3.5 billion
SPRYCEL® (dasatinib), $2.2 billion
YERVOY® (ipilimumab), $2.1 billion
ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), $811 million
REBLOZYL® (luspatercept-aamt), $717 million
ABECMA® (idecabtagene vicleucel), $388 million
EMPLICITI® (elotuzumab), $296 million
OPDUALAG™(nivolumab and relatlimab-rmbw): $252 million
ZEPOSIA® (ozanimod), $250 million
BREYANZI® (lisocabtagene maraleucel), $182 million
ONUREG® (azacitidine tablets), $124 million
INREBIC® (fedratinib), $85 million
CAMZYOS® (mavacamten), $24 million
SOTYKTU™(deucravacitinib), $8 million
Mature and other products* $1.8 billion
*Includes products that have lost exclusivity in major markets, over-the-counter (OTC) brands and royalty revenue.
Please click on the product links to see the Full Prescribing Information for ABECMA®, ABRAXANE® , BREYANZI®, CAMZYOS® ELIQUIS®, EMPLICITI®, INREBIC®, ONUREG®, OPDIVO®, OPDUALAG™, ORENCIA®, POMALYST® , REBLOZYL®, REVLIMID® , SOTYKTU™ , SPRYCEL® , YERVOY® and ZEPOSIA® including Boxed WARNINGS for ABECMA®, ABRAXANE®, BREYANZI®, CAMZYOS®, ELIQUIS®, INREBIC®, POMALYST®, REVLIMID®, and Boxed WARNINGS for YERVOY® regarding immune-mediated adverse reaction.
Bristol Myers Squibb Corporate B-roll
This B-roll includes a collection of footage of Bristol Myers Squibb campus exteriors, corporate signage, research and development, and manufacturing facilities.